Recently, RON kinase and Cathepsin K inhibitors have demonstrated a reduction in breast cancer induced osteolysis and skeletal tumor burden in preclinical and clinical studies [134, 160, 164]. The gene discussed is CTSK; the disease is breast carcinoma.